JP2022502052A5 - - Google Patents
Info
- Publication number
- JP2022502052A5 JP2022502052A5 JP2021517309A JP2021517309A JP2022502052A5 JP 2022502052 A5 JP2022502052 A5 JP 2022502052A5 JP 2021517309 A JP2021517309 A JP 2021517309A JP 2021517309 A JP2021517309 A JP 2021517309A JP 2022502052 A5 JP2022502052 A5 JP 2022502052A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- sequence
- hla
- seq
- molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024169203A JP2024177227A (ja) | 2018-09-27 | 2024-09-27 | 抗ｈｌａ－ｇ抗体、抗ｈｌａ－ｇ抗体を含む組成物、および抗ｈｌａ－ｇ抗体を使用する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862737666P | 2018-09-27 | 2018-09-27 | |
| US62/737,666 | 2018-09-27 | ||
| PCT/US2019/053158 WO2020069133A1 (en) | 2018-09-27 | 2019-09-26 | Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024169203A Division JP2024177227A (ja) | 2018-09-27 | 2024-09-27 | 抗ｈｌａ－ｇ抗体、抗ｈｌａ－ｇ抗体を含む組成物、および抗ｈｌａ－ｇ抗体を使用する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022502052A JP2022502052A (ja) | 2022-01-11 |
| JP2022502052A5 true JP2022502052A5 (enExample) | 2022-10-04 |
| JP7588068B2 JP7588068B2 (ja) | 2024-11-21 |
Family
ID=68296637
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021517309A Active JP7588068B2 (ja) | 2018-09-27 | 2019-09-26 | 抗ｈｌａ－ｇ抗体、抗ｈｌａ－ｇ抗体を含む組成物、および抗ｈｌａ－ｇ抗体を使用する方法 |
| JP2024169203A Pending JP2024177227A (ja) | 2018-09-27 | 2024-09-27 | 抗ｈｌａ－ｇ抗体、抗ｈｌａ－ｇ抗体を含む組成物、および抗ｈｌａ－ｇ抗体を使用する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024169203A Pending JP2024177227A (ja) | 2018-09-27 | 2024-09-27 | 抗ｈｌａ－ｇ抗体、抗ｈｌａ－ｇ抗体を含む組成物、および抗ｈｌａ－ｇ抗体を使用する方法 |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US11208487B2 (enExample) |
| EP (1) | EP3856780A1 (enExample) |
| JP (2) | JP7588068B2 (enExample) |
| KR (1) | KR102867868B1 (enExample) |
| CN (2) | CN115057932B (enExample) |
| AR (2) | AR116526A1 (enExample) |
| AU (1) | AU2019346598B2 (enExample) |
| BR (1) | BR112021005868A2 (enExample) |
| CA (1) | CA3114407A1 (enExample) |
| CL (2) | CL2021000761A1 (enExample) |
| CO (1) | CO2021004719A2 (enExample) |
| CR (1) | CR20210197A (enExample) |
| DO (1) | DOP2021000049A (enExample) |
| EA (1) | EA202190609A1 (enExample) |
| EC (1) | ECSP21026339A (enExample) |
| IL (1) | IL281778A (enExample) |
| MX (1) | MX2021003555A (enExample) |
| MY (1) | MY204959A (enExample) |
| NZ (1) | NZ774376A (enExample) |
| PE (1) | PE20211767A1 (enExample) |
| PH (1) | PH12021550690A1 (enExample) |
| SG (1) | SG11202103104RA (enExample) |
| TW (2) | TWI828767B (enExample) |
| UA (1) | UA129052C2 (enExample) |
| UY (1) | UY38391A (enExample) |
| WO (1) | WO2020069133A1 (enExample) |
| ZA (2) | ZA202102034B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113056483B (zh) | 2018-07-09 | 2025-08-01 | 戊瑞治疗有限公司 | 结合到ilt4的抗体 |
| BR112022011235A2 (pt) | 2019-12-09 | 2022-12-13 | Twist Bioscience Corp | Bibliotecas de variantes de ácido nucleico para receptores de adenosina |
| MX2022015498A (es) * | 2020-06-11 | 2023-01-24 | Tizona Therapeutics | Captadores de celulas inmunitarias biespecificas con especificidad de union para hla-g y otro antigeno. |
| KR20230147617A (ko) | 2021-01-21 | 2023-10-23 | 트위스트 바이오사이언스 코포레이션 | 아데노신 수용체에 관한 방법 및 조성물 |
| US11795227B2 (en) * | 2021-03-24 | 2023-10-24 | Shine-On Biomedical Co., Ltd. | Immunomodulation and anti-tumor-related nanobody and nucleic acid encoding sequence thereof, and uses of the same |
| US12012454B2 (en) * | 2021-03-24 | 2024-06-18 | China Medical University Hospital | Anti-tumor antigen nanobody and nucleic acid encoding sequence thereof, and uses of the same |
| GB202111905D0 (en) | 2021-08-19 | 2021-10-06 | UCB Biopharma SRL | Antibodies |
| CN115925930B (zh) * | 2021-11-04 | 2025-10-31 | 台州恩泽医疗中心(集团) | 一种抗hla-g1、hla-g4及hla-g5异构体分子的单克隆抗体及其用途 |
| EP4501964A4 (en) * | 2022-03-25 | 2026-04-22 | Hk Inno N Corp | SPECIFIC HLA-G ANTIBODY AND ITS USE |
| CN115819583B (zh) * | 2022-03-31 | 2026-03-03 | 台州恩泽医疗中心(集团) | 一种抗hla-g分子的单克隆抗体及其用途 |
| KR20250009591A (ko) * | 2022-04-08 | 2025-01-17 | 티조나 테라퓨틱스 | 항-hla-g 항체 및 항-egfr 항체, 항-pd1 또는 항-pd-l1 항체, 및/또는 항-cd47을 함유하는 복합 치료법 |
| KR20240002205A (ko) * | 2022-06-24 | 2024-01-04 | 에이치케이이노엔 주식회사 | 면역관문 제어 인자를 발현하는 면역세포 및 이의 용도 |
| CN117448412A (zh) * | 2022-07-26 | 2024-01-26 | 中山大学孙逸仙纪念医院 | CD158d分子、其中和抗体，及应用 |
| WO2024108568A1 (zh) * | 2022-11-25 | 2024-05-30 | 深圳先进技术研究院 | 抗人类白细胞抗原-g纳米抗体及其制备方法与应用 |
| CN119569891B (zh) * | 2023-09-06 | 2025-09-05 | 上海恩凯细胞技术有限公司 | 用于癌症治疗的靶向非经典hla分子的嵌合抗原受体的应用 |
| GB202319122D0 (en) * | 2023-12-14 | 2024-01-31 | Kbio Holdings Ltd | Antibody |
| WO2025165879A1 (en) | 2024-01-29 | 2025-08-07 | Tizona Therapeutics, Inc. | Methods of using anti-hla-g antibodies |
| WO2025245256A1 (en) | 2024-05-22 | 2025-11-27 | Tizona Therapeutics, Inc. | Combination therapy involving anti-hla-g antibodies and anti- egfr antibodies or anti-pd-1 antibodies |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| ATE135397T1 (de) | 1988-09-23 | 1996-03-15 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| WO1993016177A1 (en) | 1992-02-11 | 1993-08-19 | Cell Genesys, Inc. | Homogenotization of gene-targeting events |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| US5534615A (en) | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
| WO1996031604A1 (en) | 1995-04-07 | 1996-10-10 | The Regents Of The University Of California | Antibodies for the detection of hla-g |
| CA2321222A1 (fr) | 1998-02-20 | 1999-08-26 | Commissariat A L'energie Atomique | Methode de selection de tumeurs exprimant hla-g, sensibles a un traitement anticancereux et ses applications |
| WO2002022784A2 (en) | 2000-09-15 | 2002-03-21 | University Of Kansas Medical Center | Expression, preparation, uses, and sequence of recombinantly-derived soluble hla-g |
| WO2002061071A2 (en) | 2000-12-18 | 2002-08-08 | Dyax Corp. | Focused libraries of genetic packages |
| FR2856599A1 (fr) | 2003-06-30 | 2004-12-31 | Commissariat Energie Atomique | Utilisation de compositions contenant une forme soluble d'hla-g dans le traitement de pathologies du sang. |
| US9175064B2 (en) | 2003-11-04 | 2015-11-03 | Shuji Miyagawa | HLA-E chimeric molecule |
| PT1737891E (pt) | 2004-04-13 | 2013-04-16 | Hoffmann La Roche | Anticorpos anti p-selectina |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| CN1312182C (zh) | 2004-10-26 | 2007-04-25 | 四川新创生物科技有限公司 | 抗hla－g的单克隆抗体及分泌它的杂交瘤细胞株、癌症诊断试剂盒及其应用 |
| EP3124497B1 (en) | 2007-09-14 | 2020-04-15 | Adimab, LLC | Rationally designed, synthetic antibody libraries and uses therefor |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| EP2445935B1 (en) | 2009-06-25 | 2015-07-01 | Commissariat à l'Énergie Atomique et aux Énergies Alternatives | Multimeric polypeptides of hla-g including alpha1-alpha3 monomers and pharmaceutical uses thereof |
| CN101967191A (zh) | 2009-07-28 | 2011-02-09 | 广州天美生物技术有限公司 | Hla-g抗体制备方法及其在医学中的应用 |
| KR102318383B1 (ko) | 2010-07-16 | 2021-10-27 | 아디맵 엘엘씨 | 항체 라이브러리 |
| US20130177574A1 (en) | 2012-01-11 | 2013-07-11 | Paul I. Terasaki Foundation Laboratory | ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE |
| EP2730588A1 (en) | 2012-11-12 | 2014-05-14 | Intelectys | Antibodies and fragments thereof raised against the alpha-3 domain of HLA-G protein, methods and means for their preparation, and uses thereof |
| HK1221908A1 (zh) | 2013-04-29 | 2017-06-16 | Adimab, Llc | 多特异(polyspecificity)试剂，其制备方法和用途 |
| AU2016243128A1 (en) | 2015-03-27 | 2017-11-02 | University Of Southern California | HLA-G as a novel target for CAR T-cell immunotherapy |
| EP3842448A1 (en) | 2015-05-15 | 2021-06-30 | City of Hope | Chimeric antigen receptor compositions |
| AU2017272875B2 (en) * | 2016-06-03 | 2023-10-19 | Invectys | Anti HLA-G specific antibodies |
| TW201829463A (zh) * | 2016-11-18 | 2018-08-16 | 瑞士商赫孚孟拉羅股份公司 | 抗hla-g抗體及其用途 |
| AR114789A1 (es) | 2018-04-18 | 2020-10-14 | Hoffmann La Roche | Anticuerpos anti-hla-g y uso de los mismos |
| MX2021002316A (es) | 2018-08-31 | 2021-07-15 | Invectys SA | Receptores de antígeno quimérico frente a múltiples isoformas de hla-g. |
-
2019
- 2019-09-26 NZ NZ774376A patent/NZ774376A/en unknown
- 2019-09-26 WO PCT/US2019/053158 patent/WO2020069133A1/en not_active Ceased
- 2019-09-26 AR ARP190102737A patent/AR116526A1/es unknown
- 2019-09-26 UY UY0001038391A patent/UY38391A/es active IP Right Grant
- 2019-09-26 AU AU2019346598A patent/AU2019346598B2/en active Active
- 2019-09-26 BR BR112021005868-0A patent/BR112021005868A2/pt active Search and Examination
- 2019-09-26 CN CN202210745729.6A patent/CN115057932B/zh active Active
- 2019-09-26 EA EA202190609A patent/EA202190609A1/ru unknown
- 2019-09-26 CN CN201980074775.4A patent/CN113166243B/zh active Active
- 2019-09-26 PE PE2021000412A patent/PE20211767A1/es unknown
- 2019-09-26 MX MX2021003555A patent/MX2021003555A/es unknown
- 2019-09-26 MY MYPI2021001665A patent/MY204959A/en unknown
- 2019-09-26 US US16/584,421 patent/US11208487B2/en active Active
- 2019-09-26 TW TW108134867A patent/TWI828767B/zh active
- 2019-09-26 US US17/280,755 patent/US20210340259A1/en not_active Abandoned
- 2019-09-26 CR CR20210197A patent/CR20210197A/es unknown
- 2019-09-26 KR KR1020217012047A patent/KR102867868B1/ko active Active
- 2019-09-26 UA UAA202101599A patent/UA129052C2/uk unknown
- 2019-09-26 JP JP2021517309A patent/JP7588068B2/ja active Active
- 2019-09-26 EP EP19790902.1A patent/EP3856780A1/en active Pending
- 2019-09-26 SG SG11202103104RA patent/SG11202103104RA/en unknown
- 2019-09-26 TW TW112149190A patent/TW202438522A/zh unknown
- 2019-09-26 CA CA3114407A patent/CA3114407A1/en active Pending
-
2021
- 2021-03-24 IL IL281778A patent/IL281778A/en unknown
- 2021-03-25 CL CL2021000761A patent/CL2021000761A1/es unknown
- 2021-03-25 DO DO2021000049A patent/DOP2021000049A/es unknown
- 2021-03-25 ZA ZA2021/02034A patent/ZA202102034B/en unknown
- 2021-03-26 PH PH12021550690A patent/PH12021550690A1/en unknown
- 2021-04-15 EC ECSENADI202126339A patent/ECSP21026339A/es unknown
- 2021-04-15 CO CONC2021/0004719A patent/CO2021004719A2/es unknown
- 2021-11-18 US US17/530,072 patent/US12264199B2/en active Active
-
2022
- 2022-02-14 ZA ZA2022/01874A patent/ZA202201874B/en unknown
-
2023
- 2023-07-13 CL CL2023002048A patent/CL2023002048A1/es unknown
- 2023-08-16 AR ARP230102177A patent/AR130233A2/es unknown
-
2024
- 2024-09-27 JP JP2024169203A patent/JP2024177227A/ja active Pending
-
2025
- 2025-02-27 US US19/065,819 patent/US20250353913A1/en active Pending